Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173362 · ClinicalTrials.gov registry record · Phase 2
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
A Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06173362: Recruiting Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, sponsored by University of California, Davis.
NCT06173362 is a Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 75 participants, below the 153-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06173362, a Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.
Primary Outcome
Will be defined and graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Darolutamide
- DRUG Prednisone
- DRUG Abiraterone
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT06173362 shows while recruiting
NCT06173362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 153-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Stage IV Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06173362 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06173362 about?
NCT06173362 is a clinical study titled "Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer". This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) c...
What is the current status of trial NCT06173362?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-11-09. Estimated completion is 2027-05.
What conditions does trial NCT06173362 study?
This clinical trial studies the following conditions: Stage IV Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Advanced Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06173362?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Darolutamide (DRUG), Prednisone (DRUG), Abiraterone (DRUG).
Who is sponsoring clinical trial NCT06173362?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173362 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06173362's enrollment target sits among peer trials
75 13th of 28 higher than 16 of 28 other Stage IV Prostate Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
RECRUITING · Phase 2
-
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
RECRUITING · Phase 2
-
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI